T. Rowe Price Associates’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-181,226
| Closed | -$4.33M | – | 2985 |
|
|
2021
Q1 | $4.33M | Sell |
181,226
-1,690,847
| -90% | -$31.4M | ﹤0.01% | 1497 |
|
|
2020
Q4 | $27.3M | Sell |
1,872,073
-40,351
| -2% | -$535K | ﹤0.01% | 1135 |
|
|
2020
Q3 | $27.2M | Sell |
1,912,424
-33,554
| -2% | -$513K | ﹤0.01% | 1069 |
|
|
2020
Q2 | $28.6M | Sell |
1,945,978
-174,069
| -8% | -$1.77M | ﹤0.01% | 1033 |
|
|
2020
Q1 | $8.73M | Buy |
2,120,047
+6,468
| +0.3% | +$30.3K | ﹤0.01% | 1255 |
|
|
2019
Q4 | $10.2M | Sell |
2,113,579
-886,572
| -30% | -$4.89M | ﹤0.01% | 1309 |
|
|
2019
Q3 | $18.2M | Sell |
3,000,151
-3,589,340
| -54% | -$22.4M | ﹤0.01% | 1183 |
|
|
2019
Q2 | $42.8M | Sell |
6,589,491
-1,101,642
| -14% | -$7.76M | 0.01% | 940 |
|
|
2019
Q1 | $54.5M | Sell |
7,691,133
-453,261
| -6% | -$2.98M | 0.01% | 837 |
|
|
2018
Q4 | $39.6M | Sell |
8,144,394
-512,925
| -6% | -$2.67M | 0.01% | 907 |
|
|
2018
Q3 | $63.6M | Sell |
8,657,319
-200,447
| -2% | -$1.47M | 0.01% | 821 |
|
|
2018
Q2 | $56.5M | Sell |
8,857,766
-30,244
| -0.3% | -$200K | 0.01% | 843 |
|
|
2018
Q1 | $48.4M | Buy |
8,888,010
+56,372
| +0.6% | +$280K | 0.01% | 889 |
|
|
2017
Q4 | $36.8M | Buy |
8,831,638
+2,233,030
| +34% | +$13.4M | 0.01% | 987 |
|
|
2017
Q3 | $63.5M | Buy |
6,598,608
+1,638,377
| +33% | +$17M | 0.01% | 765 |
|
|
2017
Q2 | $58.7M | Buy |
4,960,231
+953,911
| +24% | +$12.2M | 0.01% | 773 |
|
|
2017
Q1 | $51.4M | Buy |
4,006,320
+126,506
| +3% | +$1.52M | 0.01% | 797 |
|
|
2016
Q4 | $47.5M | Buy |
3,879,814
+108,460
| +3% | +$1.29M | 0.01% | 827 |
|
|
2016
Q3 | $44.5M | Buy |
3,771,354
+1,102,600
| +41% | +$10.6M | 0.01% | 849 |
|
|
2016
Q2 | $23.2M | Sell |
2,668,754
-1,400
| -0.1% | -$9.6K | ﹤0.01% | 1050 |
|
|
2016
Q1 | $14.1M | Buy |
2,670,154
+87,300
| +3% | +$486K | ﹤0.01% | 1184 |
|
|
2015
Q4 | $20M | Buy |
2,582,854
+48,500
| +2% | +$373K | ﹤0.01% | 1083 |
|
|
2015
Q3 | $19.9M | Sell |
2,534,354
-30,200
| -1% | -$279K | ﹤0.01% | 1089 |
|
|
2015
Q2 | $23.2M | Buy |
2,564,554
+1,500
| +0.1% | +$15.1K | ﹤0.01% | 1085 |
|
|
2015
Q1 | $33.3M | Sell |
2,563,054
-5,700
| -0.2% | -$74.5K | 0.01% | 975 |
|
|
2014
Q4 | $35M | Sell |
2,568,754
-18,000
| -0.7% | -$201K | 0.01% | 964 |
|
|
2014
Q3 | $23.2M | Buy |
2,586,754
+4,400
| +0.2% | +$47.3K | 0.01% | 1068 |
|
|
2014
Q2 | $34.9M | Sell |
2,582,354
-77,546
| -3% | -$809K | 0.01% | 971 |
|
|
2014
Q1 | $26.4M | Buy |
2,659,900
+4,800
| +0.2% | +$59.6K | 0.01% | 1039 |
|
|
2013
Q4 | $35.3M | Sell |
2,655,100
-1,558,500
| -37% | -$18.9M | 0.01% | 942 |
|
|
2013
Q3 | $51.2M | Buy |
4,213,600
+319,900
| +8% | +$3.43M | 0.01% | 808 |
|
|
2013
Q2 | $40.3M | Buy |
+3,893,700
| New | +$53.7M | 0.01% | 852 |
|
T. Rowe Price Associates's GNMK Position: Q2 2021 in Review
T. Rowe Price Associates sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 181,226 shares — an estimated $4.33M sold.
T. Rowe Price Associates first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $63.6M in Q3 2018. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- T. Rowe Price Associates reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- T. Rowe Price Associates sold 181,226 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $4.33M.
- T. Rowe Price Associates first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- T. Rowe Price Associates's GenMark Diagnostics, Inc position peaked at $63.6M in Q3 2018.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.